A detailed history of Lbmc Investment Advisors, LLC transactions in Provectus Biopharmaceuticals, Inc. stock. As of the latest transaction made, Lbmc Investment Advisors, LLC holds 20,000 shares of PVCT stock, worth $2,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,000
Previous 22,000 9.09%
Holding current value
$2,000
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

SELL
$0.08 - $0.15 $160 - $300
-2,000 Reduced 9.09%
20,000 $2,000
Q3 2022

Oct 07, 2022

BUY
$0.05 - $0.06 $1,100 - $1,320
22,000 New
22,000 $1,000
Q4 2021

Mar 17, 2022

SELL
$0.05 - $0.06 $1,100 - $1,320
-22,000 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$0.06 - $0.07 $1,320 - $1,540
22,000 New
22,000 $1,000
Q2 2019

Jul 18, 2019

SELL
$0.04 - $0.06 $880 - $1,320
-22,000 Closed
0 $0
Q1 2019

Apr 26, 2019

BUY
$0.05 - $0.07 $1,100 - $1,540
22,000 New
22,000 $1,000

Others Institutions Holding PVCT

About PROVECTUS BIOPHARMACEUTICALS, INC.


  • Ticker PVCT
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 419,496,992
  • Market Cap $41.9M
  • Description
  • Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal ...
More about PVCT
Track This Portfolio

Track Lbmc Investment Advisors, LLC Portfolio

Follow Lbmc Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lbmc Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lbmc Investment Advisors, LLC with notifications on news.